Skip to main content
Duality Biotherapeutics, Inc. logo

Duality Biotherapeutics, Inc. — Investor Relations & Filings

Ticker · 9606 ISIN · KYG2929M1087 LEI · 254900HZFACBOBP9HN21 HKEX Manufacturing
Open in API
Filings indexed 68 across all filing types
Latest filing 2026-05-26 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 9606

About Duality Biotherapeutics, Inc.

https://www.dualitybiologics.com/

Duality Biotherapeutics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of next-generation Antibody-Drug Conjugates (ADCs). The company focuses on creating innovative therapeutics for oncology and autoimmune diseases. Duality operates four proprietary ADC technology platforms—DITAC, DIBAC, DIMAC, and DUPAC—which form the foundation of its robust pipeline. This pipeline currently comprises 12 self-developed ADC candidates, including 7 clinical-stage assets, next-generation bispecific ADCs, and candidates specifically designed for autoimmune conditions. Duality aims to expand the therapeutic boundaries of ADCs through its advanced design insights and execution capabilities.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is a Form FF305 “Next Day Disclosure Return” filed under Hong Kong Listing Rules, detailing changes in issued shares and treasury shares, including repurchases (share buybacks) and issuance of new shares via option exercises. It is a regulatory report of the company’s own share transactions. This matches the “Transaction in Own Shares” category (POS).
2026-05-26 English
VOLUNTARY ANNOUNCEMENT - SHARE REPURCHASE PLAN UNDER THE REPURCHASE MANDATE AND PROPOSED INCREASE IN SHAREHOLDING BY CHAIRMAN OF THE BOARD
Transaction in Own Shares Classification · 75% confidence The document is a voluntary announcement by Duality Biotherapeutics describing (1) a new Share Repurchase Plan the company will execute under its general mandate and (2) a related personal share purchase proposal by the chairman. The primary focus is the company’s repurchase of its own shares, which falls squarely under Transaction in Own Shares (POS).
2026-05-19 English
INSIDE INFORMATION NOTICE OF EXERCISE OF THE DB-1311/BNT324 COST & PROFIT/LOSS SHARING OPTION
Regulatory Filings Classification · 91% confidence The document is an “Inside Information” announcement under the Hong Kong Listing Rules describing the Company’s exercise of a cost & profit/loss sharing option under a collaboration agreement. It contains no financial statements, no fundraising or share issuance details, nor is it an earnings release or management discussion. It is a compliance/regulatory announcement of a corporate action and thus falls into the general regulatory filings category (RNS).
2026-05-13 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return filed with the Hong Kong Exchanges and Clearing Limited (HKEX) regarding movements in securities for Duality Biotherapeutics, Inc. It includes detailed information on authorized and issued share capital, movements in issued shares and treasury shares, share options exercised, confirmations of compliance with listing rules, and other regulatory confirmations. The document is structured as a regulatory return specific to share capital and share movements under HKEX Listing Rules Chapter 19B. It is not a financial report, earnings release, or management discussion. It is a regulatory filing reporting share capital changes and compliance confirmations, typical of a regulatory filing (RNS) rather than a capital/financing update (CAP) or share issue announcement (SHA) because it is a formal monthly return to the exchange. The document length is over 10,000 characters and contains substantive data, not just an announcement or certification. Therefore, the best classification is Regulatory Filings (RNS).
2026-05-07 English
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON APRIL 29, 2026
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is an announcement of the poll results from an Extraordinary General Meeting, detailing how each resolution was voted on by shareholders at the meeting. This matches the definition of a declaration of voting results and voting rights announcement (Code: DVA).
2026-04-29 English
2025 Environmental, Social and Governance Report
Environmental & Social Information Classification · 95% confidence The document is titled "Environmental, Social and Governance Report 2025" and contains detailed sections on governance, products, environment, employees, society, key performance tables, and ESG reporting indices. It is a full ESG report rather than a brief announcement or presentation. This matches the definition for Environmental & Social Information (ESG Report) category.
2026-04-26 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.